<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>http://api.elsevier.com/content/abstract/scopus_id/84899051891</prism:url><dc:identifier>SCOPUS_ID:84899051891</dc:identifier><eid>2-s2.0-84899051891</eid><pubmed-id>24686413</pubmed-id><prism:doi>10.1038/nrmicro3240</prism:doi><dc:title>Semi-synthetic artemisinin: A model for the use of synthetic biology in pharmaceutical development</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><citedby-count>15</citedby-count><prism:publicationName>Nature Reviews Microbiology</prism:publicationName><dc:publisher>
Nature Publishing Group

Houndmills
Basingstoke, Hampshire
RG21 6XS

</dc:publisher><source-id>20313</source-id><prism:issn>17401534</prism:issn><prism:volume>12</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:startingPage>355</prism:startingPage><prism:endingPage>367</prism:endingPage><prism:pageRange>355-367</prism:pageRange><prism:coverDate>2014-01-01</prism:coverDate><dc:creator><author auid="6602106652" seq="1"><ce:initials>C.J.</ce:initials><ce:indexed-name>Paddon C.J.</ce:indexed-name><ce:surname>Paddon</ce:surname><ce:given-name>Chris J.</ce:given-name><preferred-name>
<ce:initials>C.J.</ce:initials>
<ce:indexed-name>Paddon C.</ce:indexed-name>
<ce:surname>Paddon</ce:surname>
<ce:given-name>Chris J.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/6602106652</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/112620548" id="112620548"/></author></dc:creator><dc:description><abstract original="y" xml:lang="eng">
<ce:para>Recent developments in synthetic biology, combined with continued progress in systems biology and metabolic engineering, have enabled the engineering of microorganisms to produce heterologous molecules in a manner that was previously unfeasible. The successful synthesis and recent entry of semi-synthetic artemisinin into commercial production is the first demonstration of the potential of synthetic biology for the development and production of pharmaceutical agents. In this Review, we describe the metabolic engineering and synthetic biology approaches that were used to develop this important antimalarial drug precursor. This not only demonstrates the incredible potential of the available technologies but also illuminates how lessons learned from this work could be applied to the production of other pharmaceutical agents. Â© 2014 Macmillan Publishers Limited. All rights reserved.</ce:para>
</abstract></dc:description><link href="http://api.elsevier.com/content/abstract/scopus_id/84899051891" rel="self"/><link href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84899051891&amp;origin=inward" rel="scopus"/><link href="http://api.elsevier.com/content/search/scopus?query=refeid%282-s2.0-84899051891%29" rel="cited-by"/></coredata><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60007174" id="60007174"><affilname>Lawrence Berkeley National Laboratory</affilname></affiliation><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60102796" id="60102796"><affilname>Joint BioEnergy Institute, California</affilname></affiliation><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60025038" id="60025038"><affilname>UC Berkeley</affilname></affiliation><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/112620548" id="112620548"><affilname>Amyris, Inc.</affilname></affiliation><authors><author auid="6602106652" seq="1"><ce:initials>C.J.</ce:initials><ce:indexed-name>Paddon C.J.</ce:indexed-name><ce:surname>Paddon</ce:surname><ce:given-name>Chris J.</ce:given-name><preferred-name>
<ce:initials>C.J.</ce:initials>
<ce:indexed-name>Paddon C.</ce:indexed-name>
<ce:surname>Paddon</ce:surname>
<ce:given-name>Chris J.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/6602106652</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/112620548" id="112620548"/></author><author auid="7005564120" seq="2"><ce:initials>J.D.</ce:initials><ce:indexed-name>Keasling J.D.</ce:indexed-name><ce:surname>Keasling</ce:surname><ce:given-name>Jay D.</ce:given-name><preferred-name>
<ce:initials>J.D.</ce:initials>
<ce:indexed-name>Keasling J.</ce:indexed-name>
<ce:surname>Keasling</ce:surname>
<ce:given-name>Jay D.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7005564120</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60025038" id="60025038"/><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60025038" id="60025038"/><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60007174" id="60007174"/><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60102796" id="60102796"/></author></authors></abstracts-retrieval-response>
